Adagene Spon Ads Each Rep 1.25 Ord Shs (ADAG) Stock
Biotech firm developing antibodies for cancer and immune therapies. Here's the price, business snapshot, and what's worth knowing about Adagene Spon Ads Each Rep 1.25 Ord Shs in May 2026.
Adagene Inc-ADR (ADAG) is a small-cap, clinical-stage biotechnology company focused on antibody discovery and engineering to develop immuno‑oncology and immune-modulating therapies. Listed as an American Depositary Receipt, it combines research platforms with collaborations to advance therapeutic candidates from preclinical studies into clinical trials. With a market capitalisation around $89.08 million, Adagene is at an early development stage: its value is driven mainly by pipeline progress, partnership deals and trial data rather than steady revenues. Investing in clinical-stage biotech carries heightened risks — programmes can fail, dilutive financing may be needed and share price volatility is common. For investors, it’s useful to monitor trial milestones, cash runway, partnership announcements and regulatory updates. This summary is for general educational purposes only and is not personalised investment advice; investors should consider their risk tolerance and consult a financial professional before making investment decisions.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Adagene stock with a target price of $5.5, indicating good growth potential.
Financial Health
Adagene is struggling to generate significant revenue and has limited financial resources.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring ADAG
China's Biopharma Innovators: The Next Global Partnership Wave
Following GSK's major licensing deal with China's Jiangsu Hengrui, a new investment theme is emerging around Chinese pharmaceutical innovators. This theme focuses on other Chinese biopharma companies that are likely to attract similar global partnerships, driving value through their advanced drug development pipelines.
Published: July 28, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Pipeline Milestones Matter
Clinical trial readouts, INDs and partnership deals can drive revaluation, though outcomes are uncertain and timing may be unpredictable.
Collaborations and Partners
Licensing and alliances can de‑risk programmes and provide funding, but agreements vary and may affect long‑term upside.
Small‑Cap Volatility
With a sub‑$100M market cap, shares can swing sharply on news; this may suit risk‑tolerant investors but carries higher downside.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
